Oxford Gene Technology (OGT), The Molecular Genetics Company, will launch its new SureSeq solid tumour panel at the Association for Clinical Genetic Science (ACGS) meeting at Birmingham UK, on the 29–30 April 2014.
Fully validated on formalin-fixed, paraffin-embedded samples, the new 60-gene next generation sequencing hybridization-based enrichment panel offers the researchers accurate and reliable solid tumor profiling for both known and novel variants.
The content of the panel has been defined by recognized cancer experts, covering key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal. All exons of these genes are fully covered, including mutation hotspots, enabling both detection and discovery of known and novel variants respectively.
The hybridization-based SureSeq solid tumour panel minimizes PCR bias and duplications commonly associated with alternative enrichment methodologies, enabling greater run-to-run consistency. This is particularly important in situations where there is limited sample or where the ability to detect minor allele frequencies is required, such as in heterogeneous tumor samples.
Such sample types require a highly uniform and sensitive enrichment and OGT’s expert bait design ensures this by providing efficient and improved uniformity of coverage of the targeted regions, enabling all variants to be called with maximum confidence.
Providing easy access to meaningful data, the SureSeq solid tumour panel comes with OGT’s unique Variant Analysis Report, equipping researchers with the freedom to explore and retrospectively interrogate data with additional or new selection criteria, without the need for additional in-house bioinformatics resource.
Using the report, data can be easily filtered by numerous parameters, including gene, depth of coverage, somatic variants and predicted effect on the protein. In addition, all variants are fully annotated with links to various databases.